iRadimed is a high-quality small-cap franchise with a wide economic moat, best-in-class margins, and a near-perfect financial health score, but the shares trade at a forward earnings multiple of 38.6x — a valuation that leaves little margin of safety — and an elevated options skew signals meaningful near-term uncertainty.
Thesis pillars
- Wide Moat Best In Class Quality→Stable
- Elevated Options Skew Uncertainty→Stable
- Consistent Earnings Outperformance→Stable
- +1 more pillar — see the Why tab for full reasoning
iRadimed Corporation (IRMD) Stock Analysis
Oversold Bounce setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $82.22, but acceptable to hold if already in. Reasons: Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system; Concentration risk — Supplier: single-source suppliers.
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI... Read more
Hold if already holding. Not a fresh buy at $82.22, but acceptable to hold if already in. Reasons: Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system; Concentration risk — Supplier: single-source suppliers. Chart setup: Oversold RSI 23, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-09-13Recent Developments — iRadimed Corporation
Latest news
- NEWS IRadimed Corp (IRMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey — TradingKey neutral
- NEWS Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report - Yahoo Finance — Yahoo Finance positive
- NEWS Iradimed CEO Roger Susi sells $694k in common stock By Investing.com - Investing.com Australia — Investing.com Australia negative
- NEWS Iradimed CEO Roger Susi sells $694k in common stock - Investing.com — Investing.com negative
- NEWS iRadimed Corporation (IRMD) Stock Analysis: Climbs +3.48%, Eyes on $94.92 2026-05-20 - Investment Factor - Newser — Newser positive
Generated 2026-09-14T05:21:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMRidium infusion pumps and 3880 monitoring system10-K Item 1A: 'Our current revenue and profitability are significantly dependent on the sale of the MRidium MRI compatible IV infusion pump systems, the 3880 MRI compatible patient vital signs monitoring system'
- HIGHSuppliersingle-source suppliers10-K Item 1A: 'Considering our dependence on third-party suppliers, several of which are single-source suppliers, we are subject to inherent uncertainties and risks'
- LOWGeographicoutside the U.S.16%10-K Item 1A: 'Our revenues outside the U.S. in fiscal year 2025 represented approximately 16 percent of our net revenues.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $82.22, but acceptable to hold if already in. Reasons: Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system; Concentration risk — Supplier: single-source suppliers. Chart setup: Oversold RSI 23, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Target $100.30 (+22.0%), stop $78.97 (−4.1%), A.R:R 4.0:1. Score 5.7/10, moderate confidence.
Take-profit target: $100.30 (+22.0% upside). Target $100.30 (+22.0%), stop $78.97 (−4.1%), A.R:R 4.0:1. Stop-loss: $78.97.
Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system; Concentration risk — Supplier: single-source suppliers; Expensive valuation.
iRadimed Corporation trades at a P/E of 45.7 (forward 34.1). TrendMatrix value score: 3.7/10. Verdict: Hold.
8 analysts cover IRMD with a consensus score of 4.1/5. Average price target: $118.
What does iRadimed Corporation do?IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible...
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.